Sunday 11 October 2026 Export all VXRT data to Excel Powerpack

VAXART, INC.

VXRT Healthcare Biotechnology

VAXART, INC.’s revenue for fiscal 2025 (year ended December 2025) was $237.3 million, up 726.7% from fiscal 2024. In the quarter to June 2026, revenue fell 31.6%, EPS grew 14.3% and free cash flow grew 117.4%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.

0.43 0.00 0.00%
Market cap
$92.4M
P/E
2.8×
Fwd P/E
2.1×
Dividend yield
—
F-score
6/9
Altman Z
−1.06
Beneish M
3.73
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

0.00 5.83 4.07 3.81
P/S ratio
0.56 0.34 0.57 0.61
P/FCF ratio
0.00 10.64 9.92 4.42
P/Operating CF
31.76 2.63 (71.47) 53.18
P/B ratio
3.08 0.92 1.56 1.79
EV/Sales
0.37 0.08 0.34 0.35
EV/EBITDA
0.00 0.68 1.91 1.87
EV/FCF
(1.80) 2.37 5.87 2.54
Current Ratio
0.69 1.57 1.71 1.60
Net Debt/EBITDA
5.17 (1.12) (9.77) 5.11
Debt/Equity
0.00 0.00 0.00 0.00
Earnings Yield
(63.89%) 17.14% 24.59% 26.23%
Free Cash Flow Yield
(36.98%) 9.40% 10.08% 22.61%
Free Cash Flow per Share
0.01 0.13 (0.01) 0.01
Book value per Share
0.12 0.38 0.39 0.34
Free Cash Flow
2.48 30.66 (2.50) 2.75
EV/EBIT
0.00 0.99 2.28 2.14
Other line items

Show all line items

Columns are period end dates